Q-omics provides the consensus-scored RPSAP51 profile across patient tissues and cancer cell-line models. RPSAP51 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPSAP51 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, RPSAP51 RNA expression shows 8,581 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRP, and TGCT as cancer lineages where RPSAP51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP51 survival associations across molecular data types. RPSAP51 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP51 RNA expression–survival associations across cancer types. High RPSAP51 expression shows unfavorable associations in KIRC and UVM, but favorable associations in HNSC, READ, UCEC and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPSAP51 RNA expression.
This table summarizes RPSAP51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP51 shows lower tumor expression in LIHC and higher tumor expression in KIRP, LUAD and LUSC. The KIRP box plot shows higher RPSAP51 RNA expression in tumor versus normal tissue (log2 FC = +0.062, t-test p = .041).
This table shows molecular features associated with RPSAP51 in patient tissues and cancer cell lines. In patient samples, RPSAP51 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
